Histone deacetylase inhibitor sulforaphane: The phytochemical with vibrant activity against prostate cancer

Biomedicine and Pharmacotherapy

Volumn 81, Issue , 2016, Pages 250-257

  Ganai, Shabir Ahmad ^a  

^a UNIVERSITY OF KASHMIR   (India)

Author keywords

HDACs; Therapeutic intervention; TRAIL

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; SULFORAPHANE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; ISOTHIOCYANIC ACID DERIVATIVE; PLANT MEDICINAL PRODUCT; SULFORAFAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MORTALITY; CANCER PATIENT; CELL DIFFERENTIATION; CELL GROWTH; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GENE SILENCING; HISTONE ACETYLATION; HUMAN; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; REVIEW; BIOAVAILABILITY; CHEMISTRY; PROSTATIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; HISTONE DEACETYLASE INHIBITORS; HUMANS; ISOTHIOCYANATES; MALE; PHYTOCHEMICALS; PROSTATIC NEOPLASMS;

EID: 84963733639     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.04.022     Document Type: Review

References (83)

1. Abbas A., Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008, 3:300-309.
2. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
3. Takai D., Jones P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3740-3745.
4. Yang X.J., Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007, 26:5310-5318.
5. Ganai S.A. Panobinostat: the small molecule metalloenzyme inhibitor with marvelous anticancer activity. Curr. Top. Med. Chem. 2016, 16:427-434.
6. Korolev N., Allahverdi A., Lyubartsev A.P., Nordenskiold L. The polyelectrolyte properties of chromatin. Soft Matter 2012, 8:9322-9333.
7. Ganai S. Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance. Arch. Pharm. Res. 2015, 1-11.
8. Singh B.N., Zhang G., Hwa Y.L., Li J., Dowdy S.C., Jiang S.-W. Nonhistone protein acetylation as cancer therapy targets. Expert Rev. Anticancer Ther. 2010, 10:935-954.
9. Ganai S.A. Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance. Pharm. Biol. 2016, 1-10.
10. Gui C.Y., Ngo L., Xu W.S., Richon V.M., Marks P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:1241-1246.
11. Lagger G., Doetzlhofer A., Schuettengruber B., Haidweger E., Simboeck E., Tischler J., et al. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol. Cell. Biol. 2003, 23:2669-2679.
12. Wilson A.J., Byun D.S., Popova N., Murray L.B., L'Italien K., Sowa Y., et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 2006, 281:13548-13558.
13. Waltregny D., Glenisson W., Tran S.L., North B.J., Verdin E., Colige A., et al. Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J. 2005, 19:966-968.
14. Vannini A., Volpari C., Filocamo G., Casavola E.C., Brunetti M., Renzoni D., et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15064-15069.
15. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417:455-458.
16. Valenzuela-Fernandez A., Cabrero J.R., Serrador J.M., Sanchez-Madrid F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 2008, 18:291-297.
17. Matthias P., Yoshida M., Khochbin S. HDAC6 a new cellular stress surveillance factor. Cell Cycle 2008, 7:7-10.
18. Gibbs A., Schwartzman J., Deng V., Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16663-16668.
19. Park J.H., Kim S.H., Choi M.C., Lee J., Oh D.Y., Im S.A., et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem. Biophys. Res. Commun. 2008, 368:318-322.
20. Ganai S.A., Ramadoss M., Mahadevan V. Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration. Curr. Neuropharmacol. 2016, 14:55-71.
21. Bruserud O., Stapnes C., Ersvaer E., Gjertsen B.T., Ryningen A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr. Pharm. Biotechnol. 2007, 8:388-400.
22. Ganai S.A. Novel approaches towards designing of isoform-selective inhibitors against class II histone deacetylases: the acute requirement for targetted anticancer therapy. Curr. Top. Med. Chem. 2016.
23. Pal-Bhadra M., Ramaiah M.J., Reddy T.L., Krishnan A., Pushpavalli S.N., Babu K.S., et al. Plant HDAC inhibitor chrysin arrest cell growth and induce p21WAF1 by altering chromatin of STAT response element in A375 cells. BMC Cancer 2012, 12:180.
24. Son I.H., Chung I.M., Lee S.I., Yang H.D., Moon H.I. Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. Bioorg. Med. Chem. Lett. 2007, 17:4753-4755.
25. Myzak M.C., Karplus P.A., Chung F.L., Dashwood R.H. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res. 2004, 64:5767-5774.
26. Forster T., Rausch V., Zhang Y., Isayev O., Heilmann K., Schoensiegel F., et al. Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication. Oncotarget 2014, 5:1621-1634.
27. Zeng H., Trujillo O.N., Moyer M.P., Botnen J.H. Prolonged sulforaphane treatment activates survival signaling in nontumorigenic NCM460 colon cells but apoptotic signaling in tumorigenic HCT116 colon cells. Nutr. Cancer 2011, 63:248-255.
28. Li Y., Zhang T., Korkaya H., Liu S., Lee H.F., Newman B., et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin. Cancer Res. 2010, 16:2580-2590.
29. Tarozzi A., Angeloni C., Malaguti M., Morroni F., Hrelia S., Hrelia P. Sulforaphane as a potential protective phytochemical against neurodegenerative diseases. Oxid. Med. Cell. Longev. 2013, 2013:10.
30. Li Y., Karagoz G.E., Seo Y.H., Zhang T., Jiang Y., Yu Y., et al. Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90. J. Nutr. Biochem. 2012, 23:1617-1626.
31. Kallifatidis G., Labsch S., Rausch V., Mattern J., Gladkich J., Moldenhauer G., et al. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol. Ther. 2011, 19:188-195.
32. Witt O., Deubzer H.E., Milde T., Oehme I. HDAC family: what are the cancer relevant targets. Cancer Lett. 2009, 277:8-21.
33. Fischle W., Kiermer V., Dequiedt F., Verdin E. The emerging role of class II histone deacetylases. Biochem. Cell Biol. 2001, 79:337-348.
34. Mottamal M., Zheng S., Huang T.L., Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 2015, 20:3898-3941.
35. Ropero S., Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol. 2007, 1:19-25.
36. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
37. Ververis K., Hiong A., Karagiannis T.C., Licciardi P.V. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 2013, 7:47-60.
38. Ganai S.A. HDAC inhibitors entinostat and suberoylanilide hydroxamic acid (SAHA): the ray of hope for cancer therapy. Mol. Life Sci. 2015, 1-16.
39. Mai A., Massa S., Cerbara I., Valente S., Ragno R., Bottoni P., et al. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity. J. Med. Chem. 2004, 47:1098-1099.
40. Bieliauskas A.V., Pflum M.K.H. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev. 2008, 37:1402-1413.
41. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409:581-589.
42. Ganai S.A., Shanmugam K., Mahadevan V. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms. J. Biomol. Struct. Dyn. 2015, 33:374-387.
43. Ganai S. In silico approaches towards safe targeting of class I histone deacetylases. I. Mol. Life Sci. 2015, 1-9.
44. Kijima M., Yoshida M., Sugita K., Horinouchi S., Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 1993, 268:22429-22435.
45. Bhuiyan M.P., Kato T., Okauchi T., Nishino N., Maeda S., Nishino T.G., et al. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg. Med. Chem. 2006, 14:3438-3446.
46. Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., Robson C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004, 59:177-189.
47. Nakagawa M., Oda Y., Eguchi T., Aishima S., Yao T., Hosoi F., et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 2007, 18:769-774.
48. Halkidou K., Cook S., Leung H.Y., Neal D.E., Robson C.N. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur. Urol. 2004, 45:382-389.
49. Bakin R.E., Jung M.O. Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis. J. Biol. Chem. 2004, 279:51218-51225.
50. Kojima K., Ohhashi R., Fujita Y., Hamada N., Akao Y., Nozawa Y., et al. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem. Biophys. Res. Commun. 2008, 373:423-428.
51. Dai Y., Ngo D., Forman L.W., Qin D.C., Jacob J., Faller D.V. Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol. Endocrinol. 2007, 21:1807-1821.
52. Jeffery E.H., Brown A.F., Kurilich A.C., Keck A.S., Matusheski N., Klein B.P., et al. Variation in content of bioactive components in broccoli. J. Food Compost. Anal. 2003, 16:323-330.
53. Perocco P., Bronzetti G., Canistro D., Valgimigli L., Sapone A., Affatato A., et al. Glucoraphanin, the bioprecursor of the widely extolled chemopreventive agent sulforaphane found in broccoli, induces phase-I xenobiotic metabolizing enzymes and increases free radical generation in rat liver. Mutation Res 2006, 595:125-136.
54. Nakagawa K., Umeda T., Higuchi O., Tsuzuki T., Suzuki T., Miyazawa T. Evaporative light-scattering analysis of sulforaphane in broccoli samples: quality of broccoli products regarding sulforaphane contents. J. Agric. Food Chem. 2006, 54:2479-2483.
55. Thangstad O.P., Winge P., Husebye H., Bones A. The myrosinase (thioglucoside glucohydrolase) gene family in Brassicaceae. Plant Mol. Biol. 1993, 23:511-524.
56. Matusheski N.V., Swarup R., Juvik J.A., Mithen R., Bennett M., Jeffery E.H. Epithiospecifier protein from broccoli (Brassica oleracea L. ssp. italica) inhibits formation of the anticancer agent sulforaphane. J. Agric. Food Chem. 2006, 54:2069-2076.
57. Matusheski N.V., Juvik J.A., Jeffery E.H. Heating decreases epithiospecifier protein activity and increases sulforaphane formation in broccoli. Phytochemistry 2004, 65:1273-1281.
58. Saha S., Hollands W., Teucher B., Needs P.W., Narbad A., Ortori C.A., et al. Isothiocyanate concentrations and interconversion of sulforaphane to erucin in human subjects after consumption of commercial frozen broccoli compared to fresh broccoli. Mol. Nutr. Food Res. 2012, 56:1906-1916.
59. Petri N., Tannergren C., Holst B., Mellon F.A., Bao Y., Plumb G.W., et al. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab. Dispos. 2003, 31:805-813.
60. Conaway C.C., Getahun S.M., Liebes L.L., Pusateri D.J., Topham D.K., Botero-Omary M., et al. Disposition of glucosinolates and sulforaphane in humans after ingestion of steamed and fresh broccoli. Nutr. Cancer 2000, 38:168-178.
61. Jazwa A., Rojo A.I., Innamorato N.G., Hesse M., Fernández-Ruiz J., Cuadrado A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid. Redox Signal. 2011, 14:2347-2360.
62. Ye L., Dinkova-Kostova A.T., Wade K.L., Zhang Y., Shapiro T.A., Talalay P. Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin. Chim. Acta 2002, 316:43-53.
63. Singh A.V., Xiao D., Lew K.L., Dhir R., Singh S.V. Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis 2004, 25:83-90.
64. Vermeulen M., Klopping-Ketelaars I.W., van den Berg R., Vaes W.H. Bioavailability and kinetics of sulforaphane in humans after consumption of cooked versus raw broccoli. J. Agric. Food Chem. 2008, 56:10505-10509.
65. Egner P.A., Chen J.G., Wang J.B., Wu Y., Sun Y., Lu J.H., et al. Bioavailability of Sulforaphane from two broccoli sprout beverages: results of a short-term, cross-over clinical trial in Qidong, China. Cancer Prev. Res. (Phila) 2011, 4:384-395.
66. Siegel R., Ma J., Zou Z., Jemal A. Cancer Statistics, 2014 2014, 64:9-29. CA.
67. Clarke J.D., Hsu A., Yu Z., Dashwood R.H., Ho E. Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells. Mol. Nutr. Food Res. 2011, 55:999-1009.
68. Shankar S., Ganapathy S., Srivastava R.K. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin. Cancer Res. 2008, 14:6855-6866.
69. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
70. Karin M. NF-kappaB and cancer: mechanisms and targets. Mol. Carcinog. 2006, 45:355-361.
71. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat. Rev. Cancer 2006, 6:449-458.
72. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25:9-34.
73. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
74. Abbott A. Cancer: the root of the problem. Nature 2006, 442:742-743.
75. Stuckey D.W., Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol. Med. 2013, 19:685-694.
76. Labsch S., Liu L.I., Bauer N., Zhang Y., Aleksandrowicz E.W.A., Gladkich J., et al. Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells. Int. J. Oncol. 2014, 44:1470-1480.
77. Barve A., Khor T.O., Nair S., Reuhl K., Suh N., Reddy B., et al. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int. J. Cancer 2009, 124:1693-1699.
78. Barve A., Khor T.O., Reuhl K., Reddy B., Newmark H., Kong A.N. Mixed tocotrienols inhibit prostate carcinogenesis in TRAMP mice. Nutr. Cancer 2010, 62:789-794.
79. Zhang C., Su Z.-Y., Khor T.O., Shu L., Kong A.-N.T. Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation. Biochem. Pharmacol. 2013, 85:1398-1404.
80. Hurwitz A.A., Foster B.A., Allison J.P., Greenberg N.M., Kwon E.D. The TRAMP mouse as a model for prostate cancer. Curr. Protoc. Immunol. 2001, 20. Unit 20.5.
81. Singh S.V., Srivastava S.K., Choi S., Lew K.L., Antosiewicz J., Xiao D., et al. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J. Biol. Chem. 2005, 280:19911-19924.
82. Alumkal J.J., Slottke R., Schwartzman J., Cherala G., Munar M., Graff J.N., et al. A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Invest. New Drugs 2015, 33:480-489.
83. Cipolla B.G., Mandron E., Lefort J.M., Coadou Y., Della Negra E., Corbel L., et al. Effect of sulforaphane in men with biochemical recurrence after radical prostatectomy. Cancer Prev. Res. 2015, 8:712-719.